Merus Labs International Stock Price, News & Analysis (TSE:MSL)

Previous CloseN/A
Today's RangeN/A
52-Week RangeC$0.95 - C$1.76
VolumeN/A
Average Volume359,178 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Merus Labs International (TSE:MSL)

Merus Labs International logoMerus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.


Industry, Sector and Symbol:
  • Industry: N/A
  • Sub-Industry: N/A
  • Sector: N/A
  • Symbol: TSE:MSL
  • CUSIP: N/A
  • Web: www.meruslabs.com
Profitability:
  • Trailing EPS: C($0.11)
  • Net Margins: -5.18%
  • Return on Equity: -2.51%
  • Return on Assets: -1.32%
Misc:
  • Outstanding Shares: 117,355,000
 

Frequently Asked Questions for Merus Labs International (TSE:MSL)

What is Merus Labs International's stock symbol?

Merus Labs International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MSL."

Where is Merus Labs International's stock going? Where will Merus Labs International's stock price be in 2017?

5 Wall Street analysts have issued 1-year target prices for Merus Labs International's stock. Their predictions range from C$1.00 to C$3.00. On average, they anticipate Merus Labs International's share price to reach C$1.99 in the next year. View Analyst Ratings for Merus Labs International.

Who are some of Merus Labs International's key competitors?

Who are Merus Labs International's key executives?

Merus Labs International's management team includes the folowing people:

  • Michael S. Cloutier, Independent Chairman of the Board
  • Barry Fishman, Chief Executive Officer, Director
  • Michael Scott Bumby, Chief Financial Officer
  • Robert McLay, Vice President - Sales and Marketing
  • Frank Rotmann, Vice President and Head of European Operations
  • Robert Bloch M.D., Director
  • Theresa Sheila Firestone, Independent Director
  • David D. Guebert CPA, Independent Director
  • Robert S. Pollock, Independent Director
  • Timothy G. Sorensen, Independent Director

How do I buy Merus Labs International stock?

Shares of Merus Labs International and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How can I contact Merus Labs International?

Merus Labs International's mailing address is 100 Wellington St. West Suite 2110 Stn Toronto Dom PO Box 151, TORONTO, ON M5K 1H1, Canada. The specialty pharmaceutical company can be reached via phone at +1-905-7260995.


MarketBeat Community Rating for Merus Labs International (TSE MSL)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  252
MarketBeat's community ratings are surveys of what our community members think about Merus Labs International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Merus Labs International (TSE:MSL)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 4 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: C$1.99

Consensus Price Target History for Merus Labs International (TSE:MSL)

Price Target History for Merus Labs International (TSE:MSL)

Analysts' Ratings History for Merus Labs International (TSE:MSL)

Show:
DateFirmActionRatingPrice TargetDetails
5/15/2017CIBCBoost Price TargetC$1.40 -> C$1.65View Rating Details
5/12/2017ScotiabankBoost Price TargetSector PerformC$1.25 -> C$1.65View Rating Details
5/12/2017TD SecuritiesLower Price TargetBuy -> TenderC$3.00 -> C$1.65View Rating Details
2/13/2017Bloom BurtonReiterated RatingHoldView Rating Details
12/15/2016Paradigm CapitalLower Price TargetHoldC$1.60 -> C$1.00View Rating Details
12/15/2016Canaccord GenuityLower Price TargetBuyC$3.50 -> C$3.00View Rating Details
12/15/2016Royal Bank Of CanadaLower Price TargetC$3.50 -> C$3.00View Rating Details
2/2/2016CormarkUpgradeSpeculative Buy -> BuyView Rating Details
2/2/2016MackieBoost Price TargetHoldC$1.90 -> C$2.30View Rating Details
2/2/2016Dundee SecuritiesBoost Price TargetBuyC$3.50 -> C$3.60View Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History for Merus Labs International (TSE:MSL)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Merus Labs International (TSE:MSL)
2017 EPS Consensus Estimate: ($0.03)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.06)($0.02)($0.04)
Q2 20172($0.01)($0.01)($0.01)
Q3 20171$0.00$0.00$0.00
Q4 20171$0.02$0.02$0.02
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Merus Labs International (TSE:MSL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Merus Labs International (TSE MSL)

Insider Trades by Quarter for Merus Labs International (TSE:MSL)

Insider Trades by Quarter for Merus Labs International (TSE MSL)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/11/2016Andrew PatientInsiderBuy10,000C$1.90C$19,000.00
12/10/2015Barry FishmanDirectorBuy100,000C$1.72C$172,270.00
12/10/2015Robert MclayInsiderBuy6,000C$0.00C$0.00
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Merus Labs International (TSE:MSL)

Latest Headlines for Merus Labs International (TSE MSL)

Source:
DateHeadline
ABcann Global Strengthens Board and Executive TeamABcann Global Strengthens Board and Executive Team
finance.yahoo.com - November 18 at 5:31 AM
Merus Labs International Inc (MSL) Receives Consensus Recommendation of "Hold" from AnalystsMerus Labs International Inc (MSL) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 8 at 8:40 PM
Norgine BV completes acquisition of Merus Labs International Inc. strengthening its leading position in the European ... - PR Newswire (press release)Norgine BV completes acquisition of Merus Labs International Inc. strengthening its leading position in the European ... - PR Newswire (press release)
www.prnewswire.com - July 18 at 6:27 AM
Merus Labs International Inc (MSL) Given Average Rating of "Hold" by BrokeragesMerus Labs International Inc (MSL) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - July 14 at 8:20 PM
Merus Labs International Inc. files Management Information Circular for Proposed Acquisition by Norgine B.V. - PR Newswire (press release)Merus Labs International Inc. files Management Information Circular for Proposed Acquisition by Norgine B.V. - PR Newswire (press release)
www.prnewswire.com - June 6 at 12:20 AM
Merus Labs International Inc. Obtains Interim Order for Plan of Arrangement - PR Newswire (press release)Merus Labs International Inc. Obtains Interim Order for Plan of Arrangement - PR Newswire (press release)
www.prnewswire.com - June 3 at 1:04 AM
BRIEF-Merus Labs and Norgine enter into a definitive arrangement agreementBRIEF-Merus Labs and Norgine enter into a definitive arrangement agreement
www.reuters.com - May 12 at 7:16 PM
Merus Labs Reports Fiscal Q2 2017 Results - PR Newswire (press release)Merus Labs Reports Fiscal Q2 2017 Results - PR Newswire (press release)
www.prnewswire.com - May 11 at 7:28 AM
Merus Labs and Norgine Enter into a Definitive Arrangement Agreement - PR Newswire (press release)Merus Labs and Norgine Enter into a Definitive Arrangement Agreement - PR Newswire (press release)
www.prnewswire.com - May 11 at 7:28 AM
Merus Labs Announces Key Milestone for Sintrom® Profit Enhancing Initiative - PR Newswire (press release)Merus Labs Announces Key Milestone for Sintrom® Profit Enhancing Initiative - PR Newswire (press release)
www.prnewswire.com - May 4 at 11:45 PM
Exclusive: Merus Labs hires Rothschild to explore options - sources - ReutersExclusive: Merus Labs hires Rothschild to explore options - sources - Reuters
www.reuters.com - March 2 at 9:24 AM
Merus Labs International, Inc. 2017 Q1 - Results - Earnings Call SlidesMerus Labs International, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - February 16 at 6:14 PM
Merus Labs Announces Date of Fiscal Q1 2017 Earnings Release - PR Newswire (press release)Merus Labs Announces Date of Fiscal Q1 2017 Earnings Release - PR Newswire (press release)
www.prnewswire.com - February 10 at 12:45 AM
Merus Labs International, Inc. 2016 Q4 - Results - Earnings Call SlidesMerus Labs International, Inc. 2016 Q4 - Results - Earnings Call Slides
seekingalpha.com - December 15 at 7:28 PM
Merus Labs International Inc.Merus Labs International Inc.
www.baystreet.ca - December 14 at 7:21 PM

Social Media

Financials

Financials are not available for this stock.

Chart

Merus Labs International (TSE MSL) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.